Sanofi licensed ADEL’s tau‑targeting candidate ADEL‑Y01 for $80 million upfront, taking global rights to a South Korean biotech’s anti‑tau program. The deal follows a second Sanofi Alzheimer’s pact reported the same week that can total roughly $1 billion in potential biobucks, marking an aggressive mid‑late‑stage portfolio build in neurodegeneration. Sanofi will advance ADEL‑Y01, an antibody program intended for Alzheimer’s disease, under the licensing terms disclosed; the company described the pact as the second Alzheimer’s deal in a busy week for its R&D business development team. The transaction signals Sanofi’s continued push to replenish CNS assets through external deals rather than internal discovery alone. For ADEL, the deal provides near‑term validation and cash to accelerate clinical development; for Sanofi, the dual transactions diversify its Alzheimer’s risk across multiple mechanisms and geographies.